PL3755816T3 - Sposoby wykrywania i leczenia nowotworu gruczołu krokowego - Google Patents

Sposoby wykrywania i leczenia nowotworu gruczołu krokowego

Info

Publication number
PL3755816T3
PL3755816T3 PL19709298.4T PL19709298T PL3755816T3 PL 3755816 T3 PL3755816 T3 PL 3755816T3 PL 19709298 T PL19709298 T PL 19709298T PL 3755816 T3 PL3755816 T3 PL 3755816T3
Authority
PL
Poland
Prior art keywords
treatment
methods
prostate cancer
cancer detection
detection
Prior art date
Application number
PL19709298.4T
Other languages
English (en)
Polish (pl)
Inventor
Mark Kidd
Ignat Drozdov
Irvin Mark MODLIN
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of PL3755816T3 publication Critical patent/PL3755816T3/pl

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19709298.4T 2018-02-22 2019-02-21 Sposoby wykrywania i leczenia nowotworu gruczołu krokowego PL3755816T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633675P 2018-02-22 2018-02-22
PCT/US2019/018878 WO2019165021A1 (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment

Publications (1)

Publication Number Publication Date
PL3755816T3 true PL3755816T3 (pl) 2025-06-30

Family

ID=65686083

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19709298.4T PL3755816T3 (pl) 2018-02-22 2019-02-21 Sposoby wykrywania i leczenia nowotworu gruczołu krokowego

Country Status (15)

Country Link
US (3) US11410748B2 (enExample)
EP (2) EP4538393A3 (enExample)
JP (2) JP7662337B2 (enExample)
KR (2) KR20260018206A (enExample)
CN (2) CN112673115B (enExample)
AU (2) AU2019224025B2 (enExample)
BR (1) BR112020016989A2 (enExample)
CA (1) CA3091647A1 (enExample)
DK (1) DK3755816T3 (enExample)
ES (1) ES3023842T3 (enExample)
IL (1) IL276748A (enExample)
MX (2) MX2020008702A (enExample)
PL (1) PL3755816T3 (enExample)
SG (1) SG11202007922XA (enExample)
WO (1) WO2019165021A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
US20230049979A1 (en) * 2020-02-06 2023-02-16 OncoHost Ltd. Machine learning prediction of therapy response
IL310769A (en) 2021-08-11 2024-04-01 Oncohost Ltd Predicting patient response
US20230326554A1 (en) * 2022-04-08 2023-10-12 Rutgers, The State University Of New Jersey Identifying treatment response signatures
WO2024081796A1 (en) 2022-10-12 2024-04-18 Liquid Biopsy Research LLC Methods for prostate cancer detection in saliva
GB2623570B (en) * 2022-10-21 2025-07-23 Wobble Genomics Ltd Method and products for biomarker identification
KR102891032B1 (ko) * 2022-12-29 2025-12-03 재단법인대구경북과학기술원 혈액 단구세포 전사체 생체표지자를 이용한 전이성 전립선암 진단용 바이오마커 및 이의 용도
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用
CN119964650B (zh) * 2024-12-24 2025-09-30 深圳大学 一种基于集成学习的基因调控网络推断方法和系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656140A1 (en) * 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
CA3081061C (en) * 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
MX351626B (es) 2012-01-31 2017-10-23 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
WO2014012176A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer
EP2882869A4 (en) * 2012-08-07 2016-04-20 Jackson H M Found Military Med PROSTATE CANCER GENE EXPRESSION PROFILE
MY182773A (en) * 2012-11-20 2021-02-05 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
CN105209636A (zh) * 2013-03-15 2015-12-30 麦塔马克基因股份有限公司 用于癌症预后的组合物和方法
CN105658810B (zh) * 2013-06-13 2020-08-21 南澳大学 用于检测前列腺癌的方法
CA2920429C (en) 2013-08-06 2021-11-16 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
EP3214444A1 (en) 2016-03-04 2017-09-06 AIT Austrian Institute of Technology GmbH Prostate cancer diagnostic method and means

Also Published As

Publication number Publication date
AU2025238057A1 (en) 2025-11-27
SG11202007922XA (en) 2020-09-29
AU2019224025B2 (en) 2025-06-26
US20190259471A1 (en) 2019-08-22
JP2021514624A (ja) 2021-06-17
IL276748A (en) 2020-10-29
US20230298695A1 (en) 2023-09-21
DK3755816T3 (da) 2025-04-28
KR102921718B1 (ko) 2026-02-03
KR20260018206A (ko) 2026-02-06
ES3023842T3 (en) 2025-06-03
US20260066046A1 (en) 2026-03-05
JP7662337B2 (ja) 2025-04-15
AU2019224025A1 (en) 2020-09-10
US11410748B2 (en) 2022-08-09
WO2019165021A1 (en) 2019-08-29
JP2025096376A (ja) 2025-06-26
MX2020008702A (es) 2020-09-25
CA3091647A1 (en) 2019-08-29
MX2025000449A (es) 2025-03-07
CN119932188A (zh) 2025-05-06
BR112020016989A2 (pt) 2020-12-29
EP3755816A1 (en) 2020-12-30
CN112673115B (zh) 2025-02-18
EP4538393A3 (en) 2025-07-02
KR20200123450A (ko) 2020-10-29
CN112673115A (zh) 2021-04-16
EP3755816B1 (en) 2025-02-12
EP4538393A2 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
IL276748A (en) Methods for the detection and treatment of prostate cancer
IL274246A (en) Methods for diagnosing and treating cancer
IL268396A (en) Diagnostic and therapeutic methods for cancer
SG11202001010UA (en) Methods and materials for assessing and treating cancer
IL273071A (en) Treatment and diagnosis methods for cancer
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
ZA202006008B (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
IL262223A (en) Methods for monitoring and treating cancer
CA3249284A1 (en) Prostate cancer detection kit or device, and detection method
EP3891294A4 (en) METHODS OF TREATMENT OF CASTRATION-RESISTANT AND CASTRATION-SENSITIVE PROSTATE CANCER
PT3490560T (pt) Niraparib para utilização num método de tratamento de cancro da próstata
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
GB2575389B (en) System and method for prostate cancer treatment under local anesthesia
IL276089A (en) Methods for colon cancer detection and treatment monitoring
SG11202103589XA (en) Materials and methods for treating cancer
GB201915469D0 (en) Cancer detection methods
IL280830A (en) Bracelets for use in cancer treatment methods
IL265675A (en) Methods for diagnosis and treatment of prostate cancer resistant to abiraterone acetate-glucocorticoid or sensitive to metastatic castration
SG11202001796SA (en) Bacteria for targeting tumors and treating cancer
IL274714A (en) Methods and materials for cancer assessment and treatment
IL269121A (en) Usl-311 for use in the treatment of cancer
GB201609402D0 (en) Materials and methods for treating cancer
GB201819026D0 (en) Means and methods for treating cancer
GB201909135D0 (en) Means and methods for treating cancer
GB201720089D0 (en) Means and methods for treating cancer